US 12,092,634 B2
Methods for quantifying IL-33
Michael Partridge, Eastchester, NY (US); Giane Oliveira Sumner, Mahwah, NJ (US); and Joshua Zylstra, South Kent, CT (US)
Appl. No. 17/046,200
Filed by Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
PCT Filed Apr. 10, 2019, PCT No. PCT/US2019/026699
§ 371(c)(1), (2) Date Oct. 8, 2020,
PCT Pub. No. WO2019/199910, PCT Pub. Date Oct. 17, 2019.
Claims priority of provisional application 62/655,887, filed on Apr. 11, 2018.
Prior Publication US 2021/0033600 A1, Feb. 4, 2021
Int. Cl. G01N 33/53 (2006.01); G01N 33/68 (2006.01)
CPC G01N 33/5306 (2013.01) [G01N 33/6869 (2013.01); G01N 2333/54 (2013.01)] 30 Claims
OG exemplary drawing
 
1. A method of decreasing IL-33 assay interference, comprising the steps of:
acidifying a sample comprising blood, serum, or plasma to a pH of 3 to 5 to dissociate IL-33 from IL-33 complexes in the sample, wherein acidifying the sample includes adding a denaturing agent to the sample;
subsequently neutralizing the acidified sample with a buffered basic solution comprising a detection reagent, wherein the detection reagent does not compete for binding to IL-33;
adding a capture reagent to the sample; and
detecting the detection reagent, wherein the quantity of detection reagent detected correlates to the quantity of IL-33 in the sample.